Helen McShane is currently Professor of Vaccinology at the University of Oxford, Director of the NIHR Oxford Biomedical Research Centre, Deputy Head, Medical Sciences Division and an Honorary Consultant in Infectious Diseases.
Since 2001, Helen has lead a TB vaccine research group at the University of Oxford. She led the development of MVA85A, the first new TB vaccine candidate to enter efficacy testing. She collaborates with several research groups across Africa in TB vaccine clinical trials. For the last 10 years, Helen has been developing a controlled human infection model using BCG as a surrogate mycobacterial challenge agent. These studies initially delivered BCG intradermally, and more recently have delivered BCG by aerosol direct to the respiratory mucosa.
